AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended) An anti-tumor agent comprising
- (a) one or more anti-inflammatory active substances selected from the group consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, and cortisol, and
- (b) a tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide and a salt thereof.

2. - 10. (Canceled)

- 11. (Previously Presented) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride.
- 12. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.
- 13. (Original) The anti-tumor agent according to Claim 12, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

- 14. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.
- 15. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg
- 16. (Withdrawn; Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising
- (a) an effective amount of one or more an anti-inflammatory active substances selected from the group consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, and cortisol, and
- (b) an effective amount of a tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide and a salt thereof.
- 17. (Withdrawn) The method according to Claim 16, wherein said subject in need thereof is a human.
- 18. (Withdrawn) The method according to Claim 16, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

19. (Withdrawn) The method according to Claim 16, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

20. - 21. (Canceled)

- 22. (Withdrawn; Currently Amended) A method for treatment of tumors, comprising administering to a subject in need thereof
- (a) a composition comprising an effective amount of a tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide and a salt thereof; and
- (b) a composition comprising an effective amount of one or more anti-inflammatory active substances selected from the group consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, and cortisol.
- 23. (Withdrawn) The method according to Claim 22, wherein (a) and (b) are administered simultaneously or sequentially.
- 24. (Withdrawn) The method according to Claim 22, wherein said subject in need thereof is a human.
- 25. (Withdrawn) The method according to Claim 22, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

26. (Withdrawn) The method according to Claim 22, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

27. - 29. (Canceled)

- 30. (Currently Amended) An anti-tumor agent comprising
- (a) an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and
- (b) one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, fiavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol.

31. (Canceled)

32. (Currently Amended) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is a combretastine selected from the group consisting of combretastines and stilbenes, and the anti-inflammatory active substance is Dexamethasone.

33. - 34. (Canceled)

35. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.

36. (Previously Presented) The anti-tumor agent according to Claim 35, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

37. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.

38. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

39. (Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising

6

- (a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting

 Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and
- (b) one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, fiavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol.
- 40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.
- 41. (Previously Presented) The method according to Claim 39, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.
- 42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.
 - 43. (Canceled)

- 44. (Currently Amended) A method for treatment of tumors, comprising administering to a subject in need thereof
- (a) a composition comprising and effective amount of one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, fiavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol; and
- (b) a composition comprising an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.
- 45. (Previously Presented) The method according to Claim 44, wherein (a) and (b) are administered simultaneously or sequentially.
- 46. (Previously Presented) The method according to Claim 44, wherein said subject in need thereof is a human.
- 47. (Previously Presented) The method according to Claim 44, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

48. (Previously Presented) The method according to Claim 44, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

49. (Canceled)